imino(methyl)(pyridin-4-yl)-λ⁶-sulfanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: imino(methyl)(pyridin-4-yl)-λ⁶-sulfanone
• 英文别名: S-Methyl-S-(4-pyridinyl) sulfoximine；imino-methyl-oxo-pyridin-4-yl-λ6-sulfane
• 化学式: C₆H₈N₂OS
• 分子量: 156.208
• InChiKey: ZPCGCFGKAOWNSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  62.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  imino(methyl)(pyridin-4-yl)-λ⁶-sulfanone 、 2-氯苯基硼酸 在 copper diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery

  摘要：

  Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored variants of the common sulfone or sulfonamide motif. In this study, we report the physicochemical and in vitro properties of sulfoximines and compare them with related analogs and isosteres. Furthermore, we present a matched molecular pair analysis of compounds from drug discovery projects within Boehringer Ingelheim. We demonstrate that the sulfoximine moiety is a chemically stable, comparatively polar and weakly basic functional group, often leading to favorable aqueous solubility, permeability and metabolic stability. Moreover, their additional vectors at nitrogen enable simple chemical modifications and thus facilitate exploration and fine-tuning of the molecular properties. We conclude that sulfoximines and their congeners do not exhibit any intrinsic flaw but significantly enrich the toolbox of medicinal chemists. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.09.091
• 作为产物：
  描述：

  吡啶-4(1H)-硫酮 在 ammonium carbamate 、 碘苯二乙酸 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 imino(methyl)(pyridin-4-yl)-λ⁶-sulfanone
  参考文献：
  名称：

  [EN] SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND
  [FR] COMPOSÉ INHIBITEUR DE L'ATR CONTENANT UNE SULFOXIMINE
  [ZH] 含有亚磺酰亚胺基的ATR抑制剂化合物

  摘要：

  一种式(I)所示的含有亚磺酰亚胺基的ATR抑制剂化合物、其制备方法、含有该化合物的药物组合物、以及其在治疗与ATR相关或由ATR介导的疾病和/或病症中的用途。

  公开号：

  WO2022237875A1

文献信息

• SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：BLUM Andreas

  公开号：US20140135309A1

  公开（公告）日：2014-05-15

  This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R 1 and R 2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

  这项发明涉及公式I的新型磺酰胺取代的喹唑啉衍生物，其中Ar、R1和R2如本文所定义，并且它们作为MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）激酶抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗或改善MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）介导的疾病的药剂的方法。
• [EN] SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] QUINAZOLINES SUBSTITUÉES PAR SULFOXIMINE POUR COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014072244A1

  公开（公告）日：2014-05-15

  This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

  这项发明涉及一种新型的配方(I)的磺酰胺取代喹唑啉衍生物，其中Ar、R1和R2如描述和声明中所定义，并且它们作为MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）激酶抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗或改善MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）介导的疾病的药剂的方法。
• [EN] NEW AZABENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015007669A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds of general formula (I), wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中基团R1、R2、X和Y的定义如权利要求书中所述，该化合物具有有价值的药理特性，特别是与AMP-活化蛋白激酶（AMPK）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• NEW AZABENZIMIDAZOLE DERIVATIVES
  申请人：HIMMELSBACH Frank

  公开号：US20150025065A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds of general formula I, wherein the group R 1 , R 2 , X and Y are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物，其中基团R1、R2、X和Y的定义如权利要求1中所述，具有有价值的药理特性，特别是与AMP-活化蛋白激酶（AMPK）结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• Ultrafast <i>N</i>-arylation of sulfoximines enabled by micellar catalysis in water
  作者：Mingyu Song、Lei Zhang、Diandian Wei、Yu He、Jiajia Jia、Heng Li、Bingxin Yuan

  DOI：10.1039/d2gc01919a

  日期：——

  Sustainable and ultrafast N-arylation of sulfoximines in water enabled by micellar catalysis.

  在胶束催化的水相条件下，实现了持续和超快速的亚磺酰亚胺的N-芳基化。